Bempedoic Acid: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
NICE (England) and SMC (Scotland) recommended or restricted bempedoic acid, while CIPM (Spain) and TLV (Sweden) did not recommend it.
Assessment has run over 5.8 years, from 13 Feb 2020 at AWMSG (Wales) to 23 Dec 2025 at TLV (Sweden).
AOTMIT (Poland) changed its position: not recommended on 13 Nov 2023, recommended by 13 Mar 2024, after a resubmission.
No assessment is on file from HAS (France), PBAC (Australia), PHARMAC (New Zealand) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 3 of 8 records date from 2023 or later.
Against its own class, bempedoic acid is an outlier: 43% of its decisive outcomes were positive, where molecules sharing ATC class C10A average 68%.
3 distinct indication wordings are recorded for bempedoic acid by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess bempedoic acid, on 13 Feb 2020; TLV (Sweden) did not open a file until 23 Dec 2025 — a wide spread of 5.8 years between the earliest and latest system to look at it.
Restriction is doing real work here: 2 of 7 decisive outcomes narrowed bempedoic acid to a subgroup rather than accepting or refusing it outright, at NICE (England) and SMC (Scotland).
2 of the 6 agencies here assessed bempedoic acid more than once, AOTMIT (Poland) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for bempedoic acid.
The full ledger for bempedoic acid reads 4 not recommended, 2 restricted, 1 recommended and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 13 Mar 2024 | Nilemdo reimbursement recommendation | recommended | source |
| CIPM (Spain) | 3 Feb 2022 | SECRETARIA DE ESTADO DE SANIDAD 34 MINISTERIO DE SANIDAD MINISTERIO DE SANIDAD Indicaciones terapéuticas autorizadas: Ni… | not financed by the SNS · art. 92 c, d | source |
| SMC (Scotland) | 12 Jul 2021 | For treatment in adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a s… | accepted (restricted) | source |
| NICE (England) | 28 Apr 2021 | NICE TA694 | recommended (optimised) | source |
| AWMSG (Wales) | 13 Feb 2020 | Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, … | excluded, NICE appraised | source |
3 further decisions for bempedoic acid, across 3 agencies, are not shown here. They include the most recent record on file, 23 Dec 2025 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 3 further source documents.
Related molecules
- alirocumab — divergent outcome (not recommended vs restricted) on a shared indication
- evolocumab — divergent outcome (not recommended vs recommended) on a shared indication
- inclisiran — divergent outcome (not recommended vs recommended) on a shared indication
- rosuvastatin — same ATC class C10A — Lipid modifying agents
- evinacumab — same ATC class C10A — Lipid modifying agents
- ezetimibe — same ATC class C10A — Lipid modifying agents
Coverage: 8 decisions for bempedoic acid from 6 agencies, 2020 to 2025. Data to 7 Sep 2026. ATC class C10A — Lipid modifying agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.